|Bid||3.0000 x 1100|
|Ask||3.2300 x 800|
|Day's Range||3.0100 - 3.1000|
|52 Week Range||1.8600 - 9.0100|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2023 - Nov 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Subscribe to Yahoo Finance Plus to view Fair Value for BNTC
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or
On August 11, 2023, Citadel Advisors LLC, a renowned investment firm, made a significant move in the stock market by acquiring a new stake in Benitec Biopharma Inc. This article provides an in-depth analysis of this transaction, the profiles of both Citadel Advisors LLC and Benitec Biopharma Inc, and the potential implications for value investors. Citadel Advisors LLC purchased 173,880 shares of Benitec Biopharma Inc at a price of $2.81 per share. This transaction marked a new holding for the firm, increasing their total shares in Benitec Biopharma Inc to 173,880.
On August 9, 2023, JANUS HENDERSON GROUP PLC, a London-based investment firm, made a significant move in the biotechnology sector by acquiring 206,170 shares of Benitec Biopharma Inc (NASDAQ:BNTC). Despite the substantial share acquisition, the impact on the firm's portfolio was not significant, with the position in BNTC representing 0% of the total portfolio. The firm now holds 9.90% of Benitec Biopharma Inc's total shares.